Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
164 hedge funds and large institutions have $633M invested in Eagle Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 55 increasing their positions, 68 reducing their positions, and 22 closing their positions.
153% more call options, than puts
Call options by funds: $983K | Put options by funds: $388K
3% more capital invested
Capital invested by funds: $617M → $633M (+$16.2M)
2% less funds holding
Funds holding: 168 → 164 (-4)
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
19% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 68
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$14.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.38M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.58M |
| 5 |
Millennium Management
New York
|
+$5.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$11.9M |
| 2 |
Goldman Sachs
New York
|
-$10.3M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$7.57M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$7.16M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$5.99M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SGAM
176
Smith Group Asset Management
Dallas,
Texas
| – | -$63K | -1,372 | Closed |
|
|
FC
177
FORA Capital
Miami,
Florida
| – | -$44K | -956 | Closed |
|
178
ClearBridge Investments
New York
| – | -$27K | -580 | Closed |
|
179
KBC Group
Brussels,
Belgium
| – | -$23K | -504 | Closed |
|
|
NFG
180
Next Financial Group
Houston,
Texas
| – | -$16K | -358 | Closed |
|
|
PHK
181
Point72 Hong Kong
Hong Kong
| – | -$9K | -186 | Closed |
|
|
WAP
182
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$2K | -45 | Closed |
|
|
CFGS
183
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$2K | -40 | Closed |
|
|
MAM
184
Meeder Asset Management
Dublin,
Ohio
| – | +$399 | +8 | New |
|
EGRX Hedge Fund Activity: Q2 2020 in Review
164 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2020, worth a combined $633M — up 2.6% from $617M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of EGRX and 18 opened new positions — a net loss of 4 holders — while 68 trimmed existing stakes and 55 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $14.1M. The largest seller was Schroder Investment Management Group, cutting an estimated $11.9M.
- 164 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2020, down from 168 in Q1 2020.
- Funds reported $633M of Eagle Pharmaceuticals, Inc. stock for Q2 2020, up 2.6% quarter-over-quarter.
- 18 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2020 and 22 closed out, a net change of -4 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2020 was Armistice Capital, an estimated $14.1M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2020 was Schroder Investment Management Group, an estimated $11.9M sold.
Based on aggregated 13F filings for Q2 2020.